Fifteen-year mortality after radical prostatectomy: Which factors are available for patient counselling?

References

• Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012;187:1259–65.
   Web of Science ®Google Scholar
• Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 2012;188:73–83.
   Google Scholar
• Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology 2012;79:626–31.
   Google Scholar
• Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009;106:37–43.
   Google Scholar
• D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163–72.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Karnes J, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011;117:2883–91.
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–17.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–5.
   PubMed Web of Science ®Google Scholar
• Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869–75.
   PubMed Web of Science ®Google Scholar
• Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881–7.
   PubMed Web of Science ®Google Scholar
• Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998;159:1599–605.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Berg A, Lilleby W, Bruland ØS, Fosså SD. 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Rad Oncol Biol Phys 2007;69:1074–83.
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P, Dubois BD, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066–73.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104–11.
   PubMed Web of Science ®Google Scholar
• Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, et al. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience. BJU Int 2012;110:E985–90.
   Web of Science ®Google Scholar
• Boorjian SA, Karnes J, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic Validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008;179:1354–61.
   PubMed Web of Science ®Google Scholar
• Boorijan SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol 2012;188:1761–6.
   Google Scholar
• Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
   PubMed Web of Science ®Google Scholar
• Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. Eur Urol 2012;62:204–9.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patients characteristics. J Urol 2012;188:73–83.
   Google Scholar
• Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, et al. A critical analysis of long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012;61:664–75.
   PubMed Web of Science ®Google Scholar
• Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 2012;110:1122–8.
   PubMed Web of Science ®Google Scholar
• Froehner M, Koch R, Litz RJ, Hakenberg OW, Wirth MP. Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy? BJU Int 2012;110:206–10.
   Google Scholar
• Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM. Effects of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int 2011;110:211–16.
   Google Scholar
• Holmstrøm B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden follow-up study. J Urol 2010;184:1322–7.
   PubMed Web of Science ®Google Scholar
• Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, et al. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? J Sex Med 2012;9:2961–9.
   Google Scholar
• Fall K, Strömberg F, Rosell J, Andrén O, Varenhorst E; South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352–7.
   PubMed Web of Science ®Google Scholar
• Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, et al. Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. Eur Radiol 2013;23:1158–66.
   PubMedGoogle Scholar